ALK B Stock Overview
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ALK-Abelló A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr.124.40 |
| 52 Week High | kr.134.50 |
| 52 Week Low | kr.69.90 |
| Beta | 0.43 |
| 1 Month Change | 0.40% |
| 3 Month Change | 13.40% |
| 1 Year Change | 44.48% |
| 3 Year Change | -7.23% |
| 5 Year Change | 120.18% |
| Change since IPO | 264.28% |
Recent News & Updates
Recent updates
ALK-Abelló A/S (CPH:ALK B) Shares Could Be 29% Below Their Intrinsic Value Estimate
Mar 06
ALK-Abelló (CPH:ALK B) Has A Pretty Healthy Balance Sheet
Jan 19With ALK-Abelló A/S (CPH:ALK B) It Looks Like You'll Get What You Pay For
Jan 01Is ALK-Abelló (CPH:ALK B) A Risky Investment?
Sep 09ALK-Abelló (CPH:ALK B) Has A Pretty Healthy Balance Sheet
Jun 11Is ALK-Abelló A/S (CPH:ALK B) Trading At A 26% Discount?
May 24ALK-Abelló (CPH:ALK B) Has A Pretty Healthy Balance Sheet
Mar 12ALK-Abelló A/S (CPH:ALK B) Shares Could Be 26% Below Their Intrinsic Value Estimate
Feb 17Investors Interested In ALK-Abelló A/S' (CPH:ALK B) Earnings
Jan 30ALK-Abelló (CPH:ALK B) Seems To Use Debt Rather Sparingly
Dec 05Is ALK-Abelló A/S (CPH:ALK B) Trading At A 32% Discount?
Nov 11Does ALK-Abelló (CPH:ALK B) Have A Healthy Balance Sheet?
Sep 01Calculating The Fair Value Of ALK-Abelló A/S (CPH:ALK B)
Aug 05We Think ALK-Abelló (CPH:ALK B) Can Manage Its Debt With Ease
May 12Estimating The Fair Value Of ALK-Abelló A/S (CPH:ALK B)
Apr 21Is Now The Time To Put ALK-Abelló (CPH:ALK B) On Your Watchlist?
Mar 31Is ALK-Abelló (CPH:ALK B) A Risky Investment?
Dec 28Calculating The Intrinsic Value Of ALK-Abelló A/S (CPH:ALK B)
Dec 07ALK-Abelló (CPH:ALK B) Has A Rock Solid Balance Sheet
Sep 11Calculating The Fair Value Of ALK-Abelló A/S (CPH:ALK B)
Aug 21ALK-Abelló (CPH:ALK B) Seems To Use Debt Quite Sensibly
May 26Estimating The Intrinsic Value Of ALK-Abelló A/S (CPH:ALK B)
May 05Here's What ALK-Abelló A/S' (CPH:ALK B) Shareholder Ownership Structure Looks Like
Mar 04Shareholder Returns
| ALK B | DK Pharmaceuticals | DK Market | |
|---|---|---|---|
| 7D | -1.0% | 3.4% | -0.004% |
| 1Y | 44.5% | 8.2% | 23.6% |
Return vs Industry: ALK B exceeded the Danish Pharmaceuticals industry which returned 7.5% over the past year.
Return vs Market: ALK B exceeded the Danish Market which returned 26.5% over the past year.
Price Volatility
| ALK B volatility | |
|---|---|
| ALK B Average Weekly Movement | 4.0% |
| Pharmaceuticals Industry Average Movement | 4.8% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in DK Market | 9.4% |
| 10% least volatile stocks in DK Market | 3.0% |
Stable Share Price: ALK B has not had significant price volatility in the past 3 months.
Volatility Over Time: ALK B's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1923 | 2,824 | Peter Halling | www.alk.net |
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including grass, ragweed, house dust mite, Japanese cedar, tree, and food.
ALK-Abelló A/S Fundamentals Summary
| ALK B fundamental statistics | |
|---|---|
| Market cap | kr.27.52b |
| Earnings (TTM) | kr.486.00m |
| Revenue (TTM) | kr.4.82b |
56.6x
P/E Ratio5.7x
P/S RatioIs ALK B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALK B income statement (TTM) | |
|---|---|
| Revenue | kr.4.82b |
| Cost of Revenue | kr.1.79b |
| Gross Profit | kr.3.04b |
| Other Expenses | kr.2.55b |
| Earnings | kr.486.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 03, 2024
| Earnings per share (EPS) | 2.20 |
| Gross Margin | 62.94% |
| Net Profit Margin | 10.07% |
| Debt/Equity Ratio | 10.4% |
How did ALK B perform over the long term?
See historical performance and comparison